Sign up to save your podcasts
Or
Share Nivolumab plus Ipilimumab in Microsatellite-Instability–High (MSI-H) Metastatic Colorectal Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Nivolumab plus Ipilimumab in Microsatellite-Instability–High (MSI-H) Metastatic Colorectal Cancer
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Nicholas Hornstein, a GI medical oncologist from Northwell Health, to discuss the recent FDA approval of nivolumab and ipilimumab for metastatic colorectal cancer with MSI-high or MMR-deficient disease, based on the CheckMate 8HW study.
Join us as we delve into:
• The significance of MSI-high status in colorectal cancer and its prevalence.
• The study design and key findings of CheckMate 8HW, including the impressive progression-free survival rates.
• The comparison of dual checkpoint inhibitors versus single-agent therapies and chemotherapy.
• Important side effects associated with the combination therapy and how to manage them.
• Insights on patient selection for immunotherapy, including considerations for age and comorbidities.
• The potential future of immunotherapy in treating not just MSI-high but also MSS colorectal cancer.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of cancer treatment.
YouTube: https://youtu.be/wJRlECiY2VA
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our previous episodes for more discussions on FDA approvals, conference highlights, and treatment algorithms. We look forward to seeing you at ASCO 2025!
#OncologyBrothers #CancerPodcast #Immunotherapy #ColorectalCancer #FDAApproval #CheckMate8HW
View all episodes
By Oncology Brothers
4.8
3939 ratings
In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Nicholas Hornstein, a GI medical oncologist from Northwell Health, to discuss the recent FDA approval of nivolumab and ipilimumab for metastatic colorectal cancer with MSI-high or MMR-deficient disease, based on the CheckMate 8HW study.
Join us as we delve into:
• The significance of MSI-high status in colorectal cancer and its prevalence.
• The study design and key findings of CheckMate 8HW, including the impressive progression-free survival rates.
• The comparison of dual checkpoint inhibitors versus single-agent therapies and chemotherapy.
• Important side effects associated with the combination therapy and how to manage them.
• Insights on patient selection for immunotherapy, including considerations for age and comorbidities.
• The potential future of immunotherapy in treating not just MSI-high but also MSS colorectal cancer.
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable insights into the evolving landscape of cancer treatment.
YouTube: https://youtu.be/wJRlECiY2VA
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our previous episodes for more discussions on FDA approvals, conference highlights, and treatment algorithms. We look forward to seeing you at ASCO 2025!
#OncologyBrothers #CancerPodcast #Immunotherapy #ColorectalCancer #FDAApproval #CheckMate8HW
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
322 Listeners
Journal of Clinical Oncology (JCO) Podcast
41 Listeners
Research To Practice | Oncology Videos
111 Listeners
JAMA Clinical Reviews
505 Listeners
ASCO Daily News
60 Listeners
Core IM | Internal Medicine Podcast
1,116 Listeners
OncoPharm
182 Listeners
ASCO Guidelines
45 Listeners
OncLive® On Air
22 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
362 Listeners
Lung Cancer Considered
28 Listeners
The Passive Income MD Podcast
277 Listeners
Oncology Today with Dr Neil Love
60 Listeners
Two Onc Docs
181 Listeners
Blood Cancer Talks
48 Listeners